The US FDA has approved GSK’s Hibsago for chronic hepatitis B, with 19% of trial participants achieving a functional cure.
Shionogi & Co., Ltd. presented new data at IDWeek 2026 that reinforce the role of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results